{"brief_title": "A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus.", "brief_summary": "The purpose of the study is to evaluate the safety and effectiveness of 12 weeks of treatment with clevudine, at one of three doses, in patients chronically infected with hepatitis B virus.", "condition": "Hepatitis B", "intervention_type": "Drug", "intervention_name": "clevudine (drug)", "criteria": "Inclusion Criteria: - HBV DNA positive with DNA levels at screening greater than or equal to 3,000,000 copies/mL. - Documented to be HBsAg positive for > 6 months OR HBsAg positive and IgM anti-HBc negative and anti-HBs negative. Patients may be HBeAg positive, and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive. - HBeAg positive and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive with positive HBsAg for the previous 6 months - AST and ALT levels which are less than or equal to 10 times the upper limit of normal. - Bilirubin levels less than or equal to 1.5 x ULN or bilirubin levels > 1.5 x ULN with diagnosis of Gilbert\u2019s disease and conjugated bilirubin within normal limits. Exclusion Criteria: - Currently receiving antiviral, immunomodulatory or corticosteroid therapy - Previous treatment with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for HBV infection - Previous treatment with interferon must have ended at least 6 months prior to screening visit - History of ascites, variceal hemorrhage or hepatic encephalopathy - Co-infection with HCV or HIV - Evidence of cirrhosis or hepatocellular carcinoma (alpha fetoprotein)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "60 Years", "healthy_volunteers": "No", "id": "NCT00044135.xml"}